Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Clinical Trials by Condition
  • Aa
  • Acute Graft Versus Host Disease


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com





  • Human Amniotic Epithelial Cells Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation
    NCT03764228
    Condition:   Acute-graft-versus-host Disease
    Intervention:   Biological: hAECs
    Sponsors:   Peking University People's Hospital;   Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
    Not yet recruiting
  • A Study Comparing Corticosteroids Alone Versus Corticosteroids and Extracorporal Photopheresis (ECP) as First-line Treatment of Standard II Acute Graft-versus-host Disease
    NCT03605940
    Condition:   Acute-graft-versus-host Disease
    Interventions:   Combination Product: Methoxsalen + ECP device;   Drug: Corticosteroids
    Sponsor:   Central Hospital, Nancy, France
    Not yet recruiting
  • Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects
    NCT03497273
    Condition:   Acute Graft-versus-host Disease
    Interventions:   Drug: Itacitinib;   Drug: Corticosteroid
    Sponsor:   Incyte Corporation
    Recruiting
  • Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
    NCT02133924
    Condition:   Acute Graft Versus Host Disease
    Interventions:   Drug: natalizumab;   Drug: steroids
    Sponsors:   John Levine;   Biogen
    Recruiting
  • Neihulizumab (AbGn-168H) in Patients With Steroid-refractory Acute Graft-versus-host Disease
    NCT03327857
    Condition:   Steroid-refractory Acute Graft-versus-Host Disease
    Intervention:   Biological: AbGn-168H
    Sponsor:   AbGenomics International, Inc.
    Recruiting
  • An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)
    NCT03339297
    Conditions:   Graft-versus-host Disease;   Acute-graft-versus-host Disease
    Interventions:   Drug: Defibrotide;   Drug: Standard of Care
    Sponsor:   Jazz Pharmaceuticals
    Recruiting
  • T-Guard as Treatment for Steroid Refractory Acute GVHD
    NCT04128319
    Condition:   Steroid-Refractory Acute Graft Versus Host Disease
    Intervention:   Drug: T-Guard
    Sponsors:   Xenikos;   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI);   National Marrow Donor Program
    Recruiting
  • ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients
    NCT04006652
    Conditions:   Acute Graft Versus Host Disease;   Haploidentical Hematopoietic Stem Cell Transplant
    Intervention:   Drug: ApoGraft
    Sponsors:   Washington University School of Medicine;   Cellect Biotechnology
    Not yet recruiting
  • Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects
    NCT03721965
    Condition:   Acute Graft-versus-host Disease
    Interventions:   Drug: Itacitinib;   Drug: Corticosteroids
    Sponsor:   Incyte Corporation
    Recruiting
  • Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease
    NCT01521039
    Conditions:   Acute Graft-versus-Host Disease;   Allogeneic Stem Cell Transplant
    Intervention:   Procedure: Blood samples
    Sponsor:   Ohio State University Comprehensive Cancer Center
    Recruiting
  • Fecal Microbiota Transplantation For The Treatment Of Gastro-Intestinal Acute GVHD
    NCT04059757
    Condition:   Gastro-Intestinal Acute Graft Versus Host Disease (GI-aGVHD)
    Intervention:   Biological: Fecal Microbiota Transplantation (FMT)
    Sponsor:   Leland Metheny
    Not yet recruiting
  • UCMSCs as Front-line Approach of Treatment for Patients With aGVHD
    NCT03847844
    Condition:   Acute-graft-versus-host Disease
    Interventions:   Biological: Umbilical cord derived mesenchymal stem cell;   Other: Placebo
    Sponsors:   Cytopeutics Sdn. Bhd.;   Universiti Tunku Abdul Rahman;   Ministry of Energy, Science, Technology, Environment and Climate Change, Malaysia
    Recruiting
  • Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease
    NCT03491215
    Condition:   Acute Graft Versus Host Disease
    Intervention:   Drug: Ruxolitinib
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • FMT In High-Risk Acute GVHD After ALLO HCT
    NCT04139577
    Conditions:   Acute Graft-Versus-Host Disease (Gvhd) Grade;   Hematopoietic Cell Transplantation;   Fecal Microbiota Transplant
    Intervention:   Biological: Fecal Microbiota Transplant
    Sponsors:   Massachusetts General Hospital;   American Cancer Society, Inc.
    Not yet recruiting
  • Clinical Trial With MSC for Graft Versus Host Disease Treatment
    NCT02687646
    Condition:   Acute Graft Versus Host Disease
    Intervention:   Drug: Adult Allogeneic Mesenchymal cells from adipose tissue.
    Sponsors:   Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud;   Andalusian Initiative for Advanced Therapies
    Recruiting
  • Fecal Microbiota Transplantation for Steroid Resistant and Steroid Dependent Gut Acute Graft Versus Host Disease
    NCT03214289
    Conditions:   Stem Cell Transplant Complications;   Graft Versus Host Disease, Acute;   Fecal Microbiota Transplantation
    Intervention:   Biological: Fecal Microbiota Transplantation
    Sponsor:   Sheba Medical Center
    Recruiting
  • CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease
    NCT03605927
    Conditions:   Graft-versus-host-disease;   GVHD;   GVHD, Acute
    Interventions:   Drug: BMS-986004;   Drug: Sirolimus;   Drug: Tacrolimus
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Bristol-Myers Squibb
    Recruiting
  • Fecal Microbiota Transplantation in Gut aGVHD Treated
    NCT03148743
    Condition:   Acute-graft-versus-host Disease
    Intervention:   Biological: Fecal microbiota
    Sponsor:   The First Affiliated Hospital of Soochow University
    Recruiting
  • Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease
    NCT01795573
    Condition:   Graft Versus Host Disease
    Intervention:   Biological: Cultured Treg cells
    Sponsor:   H. Lee Moffitt Cancer Center and Research Institute
    Recruiting
  • Fecal Transplant +/- Gut Decontamination in Preventing Acute Graft Versus Host Disease in Patients Given Broad-Spectrum Antibiotics
    NCT03862079
    Condition:   Graft-versus-host Disease Prevention
    Interventions:   Other: Best Practice;   Procedure: Fecal Microbiota Transplantation;   Drug: Nystatin;   Drug: Piperacillin-Tazobactam
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting
  • Ruxolitinib and Steroid as First Line Therapy for Acute GVHD
    NCT03701698
    Condition:   Acute GVHD
    Interventions:   Drug: Ruxolitinib Oral Tablet;   Drug: Methylprednisolone
    Sponsor:   Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
    Not yet recruiting
  • Autologous Fecal Microbiota Transplantation for Patients With Acute Graft-versus-Host Disease
    NCT03492502
    Condition:   Fecal Microbiota Transplantation in Graft vs. Host Disease
    Intervention:   Biological: Autologous Fecal Microbiota Transplantation
    Sponsor:   Rambam Health Care Campus
    Not yet recruiting
  • Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease
    NCT04112810
    Condition:   Hematologic Malignancies
    Intervention:   Drug: Tildrakizumab
    Sponsor:   Medical College of Wisconsin
    Not yet recruiting
  • Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease
    NCT04070781
    Conditions:   Steroid Refractory GVHD;   Graft Vs Host Disease
    Interventions:   Drug: Itacitinib;   Drug: Tocilizumab
    Sponsors:   Columbia University;   Incyte Corporation
    Not yet recruiting
  • To Compare the Efficacy of the Addition of Methotrexate (MTX) to Current Standard Acute Graft-versus-host Disease (GVHD) First-line Treatment With Corticosteroids
    NCT03371667
    Conditions:   Allogeneic Disease;   GVH - Graft Versus Host Reaction;   GVHD, Acute;   Stem Cell Transplant Complications
    Interventions:   Drug: Methotrexate;   Drug: Placebo
    Sponsor:   Assistance Publique - Hôpitaux de Paris
    Recruiting
  • PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis
    NCT03689465
    Condition:   Hematopoietic Stem Cell Transplantation
    Interventions:   Drug: ATG;   Drug: CTX;   Drug: Mycophenolate Mofetil;   Drug: Ciclosporin A (CsA);   Drug: methotrexate (MTX)
    Sponsor:   Nanfang Hospital of Southern Medical University
    Recruiting
  • Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation
    NCT02828878
    Condition:   Hematological Malignancies
    Intervention:   Biological: Allogeneic MPBC transplantation from matched related donor
    Sponsor:   Cellect Biotechnology
    Recruiting
  • Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
    NCT03057054
    Condition:   Malignant Neoplasm
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Lactobacillus plantarum strain 299;   Biological: Lactobacillus plantarum strain 299v;   Other: Placebo
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation
    NCT03657160
    Condition:   Hematopoietic Stem Cells
    Interventions:   Drug: Vedolizumab;   Drug: Vedolizumab Placebo
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting
  • CD24Fc for the Prevention of Acute GVHD Following Myeloablative HSCT
    NCT04095858
    Conditions:   Hematopoietic Stem Cell Transplantation;   Acute Graft Versus Host Disease;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndromes
    Interventions:   Drug: CD24Fc;   Drug: Placebo;   Drug: Methotrexate;   Drug: Tacrolimus
    Sponsor:   OncoImmune, Inc.
    Not yet recruiting
  • A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD
    NCT03763318
    Conditions:   Acute-graft-versus-host Disease;   aGVHD;   GVHD;   GVHD, Acute
    Interventions:   Biological: EQ001;   Biological: EQ001 Placebo
    Sponsors:   Equillium;   Biocon Limited
    Recruiting
  • Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute Graft Versus Host Disease (GVHD) or Poor Graft Function
    NCT00603330
    Conditions:   Graft-versus-host Disease;   Poor Graft Function;   Low Donor T-cell Chimerism
    Intervention:   Biological: Mesenchymal stem cells
    Sponsors:   University of Liege;   KU Leuven;   Maastricht University Medical Center;   Ziekenhuis Netwerk Antwerpen (ZNA);   University Hospital, Antwerp;   University Hospital, Ghent;   AZ-VUB;   AZ Sint-Jan AV;   Cliniques universitaires Saint-Luc- Université Catholique de Louvain;   University Hospital of Mont-Godinne;   Jolimont Hospital Haine Saint Paul;   Queen Fabiola Children's University Hospital
    Recruiting
  • Phase II Trial of CD24Fc for the Prevention of Acute GVHD Following Myeloablative Allogeneic HSCT
    NCT02663622
    Conditions:   Graft Versus Host Disease;   Hematopoietic Stem Cell Transplantation;   Leukemia
    Interventions:   Drug: CD24Fc;   Drug: Methotrexate;   Drug: Tacrolimus;   Drug: Placebo
    Sponsors:   OncoImmune, Inc.;   Ohio State University;   University of Michigan Rogel Cancer Center;   Indiana University School of Medicine;   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
    Recruiting
  • BMT Autologous MSCs for GvHD
    NCT02359929
    Conditions:   Graft Versus Host Disease;   Acute Graft Versus Host Disease;   Chronic Graft Versus Host Disease
    Intervention:   Biological: Autologous mesenchymal stromal cells (MSCs)
    Sponsors:   Emory University;   CURE Foundation
    Recruiting
  • Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD
    NCT02525029
    Condition:   Graft vs Host Disease
    Intervention:   Drug: Pregnyl®
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting
  • Study of PRO 140 for Prophylaxis of Acute GVHD in Patients Undergoing RIC Allogenic Stem-Cell Transplantaton
    NCT02737306
    Condition:   Graft Vs Host Disease
    Intervention:   Drug: PRO 140
    Sponsors:   CytoDyn, Inc.;   Amarex Clinical Research
    Recruiting
  • Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD)
    NCT01903473
    Conditions:   Chronic Graft-Versus-Host Disease;   Acute Graft-Versus-Host Disease;   Steroid Refractory Graft-Versus-Host Disease
    Interventions:   Drug: Rapamycin;   Other: T regulatory cells
    Sponsor:   University of Liege
    Recruiting
  • Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
    NCT02611180
    Conditions:   Acute Graft-versus-host Disease;   Acute GVHD;   Chronic Graft-versus-host Disease;   Chronic GVHD
    Interventions:   Procedure: Skin punch biopsy;   Procedure: Peripheral blood draw
    Sponsor:   Washington University School of Medicine
    Recruiting
  • Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease (GvHD) After Allogenic Stem-cell Transplantation (HSCT)
    NCT04118556
    Condition:   GVHD, Acute
    Interventions:   Biological: Decidua Stroma Cells (DSC);   Drug: Best available Treatment (BAT)
    Sponsors:   Mats Remberger;   The Swedish Research Council
    Not yet recruiting
  • Itacitinib for Low Risk GVHD
    NCT03846479
    Conditions:   Low Risk Acute Graft-versus-host Disease;   Graft-versus-host-disease;   GVHD
    Intervention:   Drug: Itacitinib
    Sponsor:   John Levine
    Recruiting
  • First Line Therapy for High Risk Acute GVHD
    NCT04061876
    Conditions:   aGVHD;   Stem Cell Transplant Complications
    Interventions:   Drug: Ruxolitinib;   Drug: Corticosteroid
    Sponsor:   Chinese PLA General Hospital
    Recruiting
  • Treatment of Steroid Refractory Gastro-intestinal Acute GVHD afteR AllogeneiC HSCT With fEcal Microbiota tranSfer
    NCT03359980
    Condition:   Fecal Microbiota Transplantation
    Intervention:   Drug: fecal microbiota transfer
    Sponsor:   MaaT Pharma
    Recruiting
  • RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation
    NCT04014790
    Conditions:   Graft Vs Host Disease;   Graft-versus-host-disease;   Acute-graft-versus-host Disease;   Prevention of aGVHD
    Interventions:   Drug: RGI-2001;   Drug: Standard of Care
    Sponsor:   Regimmune Corporation
    Recruiting
  • Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant
    NCT03924401
    Condition:   Graft Versus Host Disease
    Intervention:   Drug: Abatacept
    Sponsors:   Emory University;   Thrasher Research Fund;   Sickle Cell Transplant Advocacy & Research Alliance (STAR)
    Recruiting
  • Gut Decontamination In Pediatric Allogeneic Hematopoietic
    NCT02641236
    Conditions:   Hematopoietic Stem Cell Transplantation (HSCT);   Acute GVH Disease
    Intervention:   Drug: Vancomycin-polymyxin B
    Sponsor:   Dana-Farber Cancer Institute
    Recruiting
  • Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone
    NCT04167514
    Condition:   Graft Versus Host Disease (GVHD)
    Interventions:   Biological: Alpha-1 antitrypsin (AAT);   Drug: Placebo
    Sponsors:   CSL Behring;   Blood and Marrow Transplant Clinical Trials Network;   National Institutes of Health (NIH);   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI)
    Not yet recruiting
  • Neihulizumab for Standard-Risk Acute GVHD
    NCT04144036
    Condition:   Graft-versus-host Disease
    Intervention:   Drug: Neihulizumab
    Sponsor:   Sameem M. Abedin, MD
    Not yet recruiting
  • Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
    NCT03434730
    Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Acute Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic-Myeloproliferative Diseases;   Myeloproliferative Disorder;   Non Hodgkin Lymphoma;   Hodgkin Lymphoma;   Leukemia
    Interventions:   Radiation: Total Body Irradiation;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Drug: Tocilizumab;   Drug: Filgrastim
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting
  • TCDαβ/CD45RA Haploidentical Transplantation in Children With Leukemia
    NCT04033627
    Conditions:   Relapsed Pediatric ALL;   Acute Graft-Versus-Host Disease (Gvhd) Grade IV (Diagnosis);   Relapsed Pediatric AML
    Intervention:   Procedure: In Vitro T cells depletion using CliniMCAS system
    Sponsors:   Shanghai Children's Medical Center;   Nanfang Hospital of Southern Medical University;   Children's Hospital Of Soochow University;   Chinese University of Hong Kong;   Miltenyi Biotec GmbH
    Not yet recruiting
  • An Open Label Study of Multiple Doses of Cannabidiol in the Prevention of Acute Graft-Versus-Host Disease (GVHD)
    NCT03840512
    Condition:   Prevention aGVHD
    Intervention:   Drug: CBD
    Sponsor:   Kalytera Therapeutics Israel, Ltd.
    Recruiting
  • Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
    NCT01951885
    Conditions:   Chronic Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Biphenotypic Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Hodgkins Disease;   Chronic Lymphocytic Leukemia;   Multiple Myeloma
    Interventions:   Drug: tacrolimus;   Drug: methotrexate;   Drug: Mycophenolate mofetil;   Drug: Methotrexate (low dose)
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • MSC for Severe aGVHD
    NCT03631589
    Condition:   Steroid-resistant Severe aGVHD
    Intervention:   Biological: MSCs
    Sponsor:   Fujian Medical University
    Recruiting
  • Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation
    NCT02338232
    Condition:   GVHD
    Intervention:   Drug: Telmisartan
    Sponsor:   Hackensack Meridian Health
    Recruiting
  • Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft
    NCT03887156
    Conditions:   Acute Myeloid Leukemia in Remission;   Lymphoma in Remission;   Non-progressive Myeloproliferative Syndrome;   Myelodysplasia With Stable Blasts is Cell Number and < 10% of Blastocysts;   Acute Leukemia Biphenotypic in Remission;   Acute Lymphoblastic Leukemia
    Intervention:   Diagnostic Test: Ex vivo capacities of CD4neg INkT expansion of the peripheral blood donor with the Predictor test
    Sponsors:   Assistance Publique - Hôpitaux de Paris;   SATT;   SNC Graft Versus Host Disease;   Imagine Institute;   AXONAL-BIOSTATEM;   CERBA laboratory
    Not yet recruiting
  • Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
    NCT02743351
    Conditions:   Hematologic Malignancies;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndromes;   Chronic Myelogenous Leukemia;   Acute Graft-versus-host Disease
    Interventions:   Biological: ProTmune;   Biological: Control Arm
    Sponsor:   Fate Therapeutics
    Recruiting
  • Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies
    NCT03557749
    Conditions:   Immune and Microbial Reconstitution;   Systemic Viral Infection;   Acute-graft-versus-host Disease;   Chronic Graft-versus-host-disease;   Recurrent Malignancy;   Cytokine Release Syndrome;   Allogenic Related Donors;   Cell Therapy/Immunotherapy Patients
    Interventions:   Diagnostic Test: Blood Sample;   Diagnostic Test: Stool Sample;   Diagnostic Test: Urine Sample;   Diagnostic Test: Bronchoalveolar Lavage (BAL) fluid;   Diagnostic Test: Gastrointestinal biopsy x 2-4;   Diagnostic Test: Skin biopsy;   Diagnostic Test: Skin, mouth, and/or ocular swab;   Diagnostic Test: Apheresis Product;   Diagnostic Test: Final cellular product
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting
  • Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies
    NCT03082677
    Conditions:   Myeloid Hematologic Malignancy;   Lymphoid Hematologic Malignancy
    Intervention:   Drug: Ixazomib
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Millennium: The Takeda Oncology Company
    Recruiting
  • Fecal Microbiota Transplantation in aGvHD After ASCT
    NCT03819803
    Condition:   Graft Versus Host Disease in GI Tract
    Intervention:   Biological: Fecal microbiota transplantation
    Sponsor:   Medical University of Graz
    Recruiting
  • Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia
    NCT03970096
    Conditions:   Acute Biphenotypic Leukemia;   Acute Leukemia of Ambiguous Lineage;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Acute Undifferentiated Leukemia;   Allogeneic Hematopoietic Stem Cell Transplantation Recipient;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Donor;   Lymphoblastic Lymphoma;   Mixed Phenotype Acute Leukemia
    Interventions:   Radiation: Total-Body Irradiation;   Drug: Thiotepa;   Drug: Fludarabine;   Drug: Fludarabine Phosphate;   Drug: Tacrolimus;   Biological: Allogeneic CD34+-enriched and CD45RA-depleted PBSCs;   Drug: Methotrexate;   Biological: Anti-Thymocyte Globulin;   Drug: Cyclophosphamide;   Biological: Allogeneic CD34-positive Enriched Peripheral Blood Stem Cells;   Drug: Peripheral Blood Stem Cell
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting
  • Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC
    NCT03263767
    Condition:   Graft Versus Host Disease
    Interventions:   Drug: Fludarabine;   Drug: Clofarabine;   Radiation: Full body irradiation;   Drug: Cyclophosphamide;   Other: stem cell transplantation;   Other: nuclear cells
    Sponsor:   Nantes University Hospital
    Recruiting
  • Anti T-lymphocyte Immunoglobulin With Post Transplant Cyclophosphamide to Prevent GVHD Post Allogeneic Transplantation
    NCT03357159
    Condition:   Graft Versus Host Disease
    Interventions:   Drug: Cyclophosphamide;   Drug: anti-human T-lymphocyte immunoglobulin (ATLG)
    Sponsor:   Sheba Medical Center
    Recruiting
  • Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia
    NCT03467386
    Conditions:   Acute Myeloid Leukemia;   Hematopoietic Cell Transplant Recipient
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Tacrolimus;   Radiation: Total Marrow Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting
  • Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation
    NCT03529825
    Condition:   Microbial Colonization
    Intervention:   Drug: Rifaximin
    Sponsor:   Emory University
    Recruiting
  • Fecal Microbiota Transplantation for Steroid Resistant/Dependent Acute GI GVHD
    NCT03812705
    Condition:   Hematopoietic and Lymphoid Cell Neoplasm
    Intervention:   Biological: fecal microbiome transplantation
    Sponsor:   Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
    Recruiting
  • Preemptive Therapy With CMV-specific T Cells Infusion to Prevent Refractory CMV Infection Post Transplantation
    NCT02985775
    Condition:   CMV Infection
    Intervention:   Biological: Donor-derived CMVpp65-specific T cells
    Sponsor:   Peking University People's Hospital
    Recruiting
  • Changes in the Gut Microbiota of Patients Undergoing Allogeneic Stem Cell Transplantation (COLLECT)
    NCT03148197
    Conditions:   Acute Myeloid Leukemia;   Graft-versus-host-disease;   Allogeneic Hematopoietic Stem Cell Transplantation;   Stem Cell Transplant Complications
    Intervention:  
    Sponsor:   University of Cologne
    Recruiting
  • GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia
    NCT02799147
    Conditions:   Leukemia, Acute Lymphoblastic;   Acute Myeloid Leukemia;   Mixed-Lineage Acute Leukemias
    Interventions:   Procedure: Allogeneic stem cell transplantation;   Drug: Fludarabine monophosphate;   Drug: Busulfan;   Drug: Bendamustine
    Sponsor:   St. Petersburg State Pavlov Medical University
    Recruiting
  • TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)
    NCT03959241
    Conditions:   Acute Leukemia;   Chronic Myelogenous Leukemia (CML);   Myelodysplasia;   Lymphoma
    Interventions:   Procedure: Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate;   Drug: Tacrolimus;   Drug: Methotrexate;   Procedure: Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide;   Drug: Mycophenolate Mofetil;   Drug: Cyclophosphamide
    Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI);   National Marrow Donor Program
    Recruiting
  • Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
    NCT02416388
    Condition:   Acute Myeloid Leukemia (AML)
    Interventions:   Drug: Idarubicin;   Drug: Daunorubicin;   Drug: HD Cytarabine;   Drug: Cyclosporine;   Drug: Methotrexate;   Drug: Mycophenolic acid (MPA);   Drug: vosaroxin;   Drug: ID cytarabine
    Sponsor:   University Hospital, Angers
    Recruiting
  • Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
    NCT03755414
    Conditions:   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndromes;   Non-Hodgkin Lymphoma;   Hodgkin Disease
    Interventions:   Procedure: Stem cell transplantation;   Drug: Itacitinib;   Other: Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT);   Other: Human Activity Profile
    Sponsors:   Washington University School of Medicine;   Incyte Corporation
    Recruiting
  • Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
    NCT03779854
    Conditions:   Acute Biphenotypic Leukemia;   Acute Leukemia;   Acute Leukemia of Ambiguous Lineage;   Acute Lymphoblastic Leukemia;   Acute Undifferentiated Leukemia;   Allogeneic Hematopoietic Stem Cell Transplantation Recipient;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Blasts Under 25 Percent of Bone Marrow Nucleated Cells;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Mixed Phenotype Acute Leukemia;   Myelodysplastic Syndrome With Excess Blasts-1;   Myelodysplastic Syndrome With Excess Blasts-2
    Interventions:   Radiation: Total-Body Irradiation;   Drug: Thiotepa;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Busulfan;   Biological: Allogeneic Hematopoietic Stem Cell Transplantation (unmanipulated T cell replete BM);   Drug: Tacrolimus;   Drug: Methotrexate;   Biological: Allogeneic Hematopoietic Stem Cell Transplantation (naive T cell-depleted PBSC)
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting
  • Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT
    NCT03066466
    Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: Atorvastatin;   Drug: Methotrexate;   Drug: Tacrolimus
    Sponsor:   Loyola University
    Recruiting
  • Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies
    NCT03270748
    Condition:   Myeloid Malignancies
    Intervention:   Drug: GvHD prophylaxis
    Sponsor:   Gruppo Italiano Trapianto di Midollo Osseo
    Not yet recruiting
  • Chidamide Plus PTCy/Cyclosporine to Prevent GVHD After Myeloablative Conditioning, Matched PBSCT
    NCT03336632
    Conditions:   Leukemia, Acute;   MDS
    Interventions:   Drug: Chidamide;   Drug: Cyclophosphamide;   Drug: cyclosporine A
    Sponsor:   Sichuan University
    Not yet recruiting
  • High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
    NCT03128359
    Conditions:   Acute Leukemia;   Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma;   Graft Versus Host Disease;   Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   Secondary Myelodysplastic Syndrome
    Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Procedure: Hematopoietic Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan Hydrochloride;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting
  • Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
    NCT03192397
    Conditions:   Acute Myeloid Leukemia in Remission;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission;   Chronic Myelomonocytic Leukemia in Remission;   Graft Versus Host Disease;   Hodgkin Lymphoma;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Plasma Cell Myeloma;   Severe Aplastic Anemia;   Waldenstrom Macroglobulinemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan Hydrochloride;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting
  • A Phase 1 Study of Engineered Donor Grafts (OrcaGraft) in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
    NCT03802695
    Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndromes;   Acute Leukemia
    Intervention:   Biological: OrcaGraft
    Sponsor:   Orca Biosystems, Inc.
    Recruiting
  • Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole
    NCT03434704
    Conditions:   Transplant-Related Hematologic Malignancy;   Leukemia, Acute;   Myelodysplastic Syndromes;   Graft Vs Host Disease;   Fungal Infection
    Interventions:   Drug: Conditioning treatment "Thiotepa-Treosulfan-Fludarabine";   Procedure: PBSC graft;   Drug: GvHD prophylaxis;   Drug: Primary antifungal prophylaxis
    Sponsor:   Ciceri Fabio
    Recruiting
  • Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Unrelated Donor Blood and Marrow Transplantation
    NCT03842696
    Conditions:   Hematologic Diseases;   Acute Myeloid Leukemia in Remission;   Acute Lymphoblastic Leukemia in Remission;   Chronic Myelogenous Leukemia - Chronic Phase;   Chronic Myelogenous Leukemia, Accelerated Phase;   Chronic Myelogenous Leukemia, Blastic Phase;   Myelodysplastic Syndromes;   Mantle Cell Lymphoma;   Follicular Lymphoma;   Diffuse Large B Cell Lymphoma;   Non Hodgkin Lymphoma;   Graft Vs Host Disease;   Graft-versus-host-disease
    Interventions:   Drug: Vorinostat;   Procedure: Blood and Marrow Transplant (BMT);   Drug: Tacrolimus;   Drug: Methotrexate
    Sponsor:   University of Michigan Rogel Cancer Center
    Recruiting
  • Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT
    NCT03963024
    Conditions:   Irradiated Bone Marrow;   Transplant-Related Hematologic Malignancy;   Leukemia, Acute;   Multiple Myeloma;   Graft Vs Host Disease
    Interventions:   Drug: Conditioning treatment "Treosulfan-TMI";   Procedure: SCT;   Drug: GvHD prophylaxis
    Sponsor:   IRCCS San Raffaele
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC